Fauvet Girel
FAUV.PA
Euronext Paris24.40
EUR
- -
- -
Fauvet Girel
FAUV.PA
(Euronext Paris)
Recent
price
24.40
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- ABL Diagnostics SA (Euronext Paris: ABLD; formerly Etablissements Fauvet Girel) develops, manufactures, and markets proprietary molecular biology assays and end-to-end diagnostic solutions for infectious disease management, focusing on polymerase chain reaction (PCR) detection via UltraGene(R) technology and genotyping through next-generation sequencing (NGS) and Sanger sequencing via DeepChek(R) technology; microbiological specimen collection kits via MediaChek(R); and digital solutions including analysis software, data hosting, laboratory automation, Nadis(R) electronic medical record system, and SeqHepB. Core products encompass DeepChek(R) assays for HIV drug resistance (covering reverse transcriptase, protease, integrase genes), hepatitis B and C, SARS-CoV-2 variants, mycobacterium tuberculosis, human papillomavirus (HPV) messenger RNA, 16S RNA, RSV, Salmonella; UltraGene(R) assays for SARS-CoV-2 (including multi-variants deletions and triplex screening), dengue, Zika, Monkeypox, Clostridium; and additional offerings like ViroScore(R), TherapyEdge(R), HepatiC(R), BacterioChek, MicrobioChek. The company serves academic clinical pathology labs, private reference labs, and researchers worldwide through direct sales and exclusive distributors across all continents, with operations in Europe, North America via its wholly owned U.S. subsidiary ABL AdvancedDx Biological Laboratories USA Inc., and emerging markets; headquartered in Woippy, France, it traces roots to the historic Fauvet Girel railcar entity, reoriented post-2021 acquisition of a controlling stake by Advanced Biological Laboratories SA (Luxembourg). Recent developments include a name change from Etablissements Fauvet Girel to ABL Diagnostics SA in April 2022, reflecting its pivot to molecular diagnostics; a strategic intra-group distribution agreement with sister company CDL Pharma in the second half of 2025 to market its products; an exclusive EMEA distribution partnership with Vela Diagnostics announced in July 2025 for CE-IVD automated PCR and NGS platforms, effective January 2026 following a transition phase; additional exclusive distribution deals in Cyprus and Montenegro in October 2025 to expand global footprint; a second strategic agreement in October 2025 between parent ABL Luxembourg and Alumni Capital to boost free float, support U.S. expansion, and fund regulatory milestones in clinical genotyping; a partnership with Eurobio Scientific UK in September 2025 and with MGI at ESCMID Global 2024 for DeepChek(R) genotyping; and a liquidity contract with Allinvest Securities in April 2024.